 |
AcompliaReport |
Your INDEPENDENT source of news and reviews about the new diet drug Acomplia (rimonabant) |
||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
| Acomplia News from August 2004 -- News about rimomabant | |
Participant in Acomplia Studies Excited by 30-Pound Weight Loss |
|
One participant in the early Acomplia studies has recently reported on her experience in Newsweek magazine. When Karen Helmick got married in 1974, the 5-foot-4 blonde already tipped the scales at 165 pounds. By 2001 the pound-a-year creep had nudged her to 213. Then she heard about a trial of an experimental weight-loss drug called rimonabant. During the yearlong study in 2002, she lost 30 pounds. "I had fewer cravings," she says. "I want a lifetime supply of this stuff," the West Virginia grandmother subsequently told the Bloomberg news service. Source: Newsweek, Aug. 14, 2004turn to News Index |
|
We subscribe to the HONcode principles of the HON Foundation. This is an independent news site reporting on rimonabant, a diet drug developed by Sanofi-Synthelabo Inc., which plans to market it under the trademarked name Acomplia. Nothing on this site is intended to infringe on that trademark. Nothing on this site is intended as medical advice. The information provided here is for informational purposes only. Always consult a doctor or medical professional with questions you may have regarding a medical condition.
(c) 2004-2006 Medical Week News, Inc. All Rights Reserved
Last Updated: 11/08/2005